Growth Hormone Axis · Daily injection · Compounded 503A
Tesamorelin: the GHRH analog with the strongest visceral-fat evidence.
Tesamorelin is a stabilized 44-amino-acid analog of growth hormone-releasing hormone (GHRH). It is FDA-approved (as Egrifta) for HIV-associated lipodystrophy and is the only GHRH analog with multiple Phase III trials showing significant visceral adipose tissue reduction. Used off-label for body-composition and metabolic goals.
What Tesamorelin is
Tesamorelin is a synthetic, stabilized 44-amino-acid analog of human growth hormone-releasing hormone (GHRH). The trans-3-hexenoic acid modification at the N-terminus prevents rapid degradation by dipeptidyl peptidase IV, giving tesamorelin a longer half-life than native GHRH.
It was developed by Theratechnologies and approved by the FDA in 2010 (brand name Egrifta) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It is the only GHRH analog with that specific approval.
Outside of the HIV-lipodystrophy indication, tesamorelin is used off-label by clinicians for adults with central adiposity, age-related GH decline, and metabolic dysfunction. Compounded tesamorelin from 503A pharmacies is what kindr physicians typically prescribe.
How it works
Tesamorelin binds GHRH receptors on the somatotrophs of the anterior pituitary, stimulating pulsatile growth hormone release. Unlike exogenous HGH, the release stays pulsatile and remains under hypothalamic feedback control — preserving physiology and reducing the risk of IGF-1 overshoot.
The downstream effect is a modest, sustained rise in serum IGF-1. IGF-1 stimulates lipolysis in visceral adipose tissue more than in subcutaneous fat — the mechanistic basis for tesamorelin's selective effect on belly fat.
Phase III trials in HIV-lipodystrophy patients showed 15–18% reductions in visceral adipose tissue at 26 weeks versus placebo, measured by CT. Subcutaneous fat was largely preserved, and lipid profiles improved (triglycerides down, HDL up).
What patients use it for
Visceral fat reduction
The strongest and most replicated effect. Visceral (intra-abdominal) fat is the metabolically active fat tied to insulin resistance and cardiovascular risk — and the fat most likely to accumulate in midlife.
Improved lipid profile
Trials consistently show reductions in triglycerides and small improvements in HDL with tesamorelin therapy, independent of weight change.
Body composition
Lean body mass typically increases modestly while visceral fat decreases — a favorable shift, particularly for women in perimenopause where lean mass loss is common.
Physiologic GH support
Tesamorelin works upstream at the pituitary and preserves the natural feedback loop. This is generally better tolerated than exogenous HGH and avoids supraphysiologic IGF-1 spikes.
Evidence summary
Tesamorelin has the strongest visceral-fat evidence base of any peptide marketed for body composition. Falutz et al. (NEJM 2007) and the follow-up Phase III trials demonstrated 15–18% reductions in visceral adipose tissue at 26 weeks.
Stanley TL et al. (JAMA 2014) extended this to non-HIV populations with NAFLD, showing reductions in liver fat alongside visceral fat — early evidence the metabolic benefit generalizes.
Off-label use in healthy adults for body composition does not have the same RCT base as the HIV approval. Outcomes appear similar in clinical practice but should be discussed with an honest physician.
Dosing and clinical context
General clinical context only. Kindr Health physicians determine the appropriate dose and protocol for each patient based on history and labs. This is not a prescription or dosing recommendation.
FDA-approved dose for HIV-lipodystrophy is 2 mg subcutaneously once daily. Compounded protocols for off-label body-composition use are often dosed similarly or somewhat lower, individualized to IGF-1 response.
Administered as a subcutaneous abdominal injection, typically at bedtime to align with natural GH pulses. IGF-1 is rechecked at 6–12 weeks and dose is adjusted to keep IGF-1 in the upper-normal range for age — never supraphysiologic.
Treatment course is typically 3–6 months with reassessment. Tesamorelin is not intended as indefinite therapy without periodic re-evaluation of benefit and labs.
Safety and contraindications
Common side effects: injection-site reaction, arthralgias, peripheral edema, transient hyperglycemia. Most are mild and self-limited.
Contraindications: pregnancy, active malignancy, pituitary disease, severe untreated diabetes. Caution with concurrent corticosteroids.
Baseline labs required: IGF-1, fasting glucose / HbA1c, comprehensive metabolic panel. Repeat IGF-1 at 6 and 12 weeks. Stop if IGF-1 rises above the age-adjusted normal range.
Who it's typically considered for
- Adults with central/visceral adiposity not responding to lifestyle alone
- Women in perimenopause and menopause with new belly-fat accumulation
- Patients with metabolic dysfunction (elevated triglycerides, insulin resistance) needing a GH-axis lever
- Patients on TRT or HRT who want a body-composition adjunct under physician supervision
Frequently asked questions
Is tesamorelin FDA-approved?
Yes — tesamorelin (brand: Egrifta, Egrifta SV) is FDA-approved for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Use for general body composition or anti-aging is off-label. Compounded tesamorelin is not FDA-approved.
How is tesamorelin different from sermorelin?
Both are GHRH analogs. Tesamorelin is a 44-amino-acid stabilized analog with a longer half-life and the strongest visceral-fat evidence base. Sermorelin is a 29-amino-acid analog, shorter-acting, gentler, often preferred for sleep and recovery. Tesamorelin is the more potent GH lever; sermorelin is the lower-intensity entry point.
How is tesamorelin different from HGH?
HGH (somatropin) introduces growth hormone directly, bypassing the pituitary. Tesamorelin tells your own pituitary to produce GH in its natural pulsatile pattern, preserving feedback control. The result is a more physiologic IGF-1 rise with less risk of supraphysiologic levels.
How long until visceral fat changes?
Trial data show measurable visceral fat reduction at 12 weeks, with the largest effect at 26 weeks. Most patients are reassessed at 12 weeks (labs + waist measurement) and continued if benefit is evident.
Will tesamorelin affect blood sugar?
Transient mild glucose elevation is the most common metabolic effect — usually within normal range, occasionally not. Patients with prediabetes or diabetes need closer monitoring. Tesamorelin is not contraindicated in well-controlled diabetes but it is not first-line in poorly controlled diabetes.
Can I use tesamorelin with semaglutide or tirzepatide?
Yes, the combination is used in clinical practice — GLP-1s drive overall weight and appetite, tesamorelin selectively addresses visceral fat. The physician monitors IGF-1, glucose, and overall composition.
Is tesamorelin safe long-term?
The FDA-approval trials extended to 52 weeks with acceptable safety. Indefinite use is not recommended without periodic re-evaluation. The unknown is whether sustained mild IGF-1 elevation over many years affects cancer risk — an active research question.
Sources
- Falutz J et al. Effects of tesamorelin on abdominal fat in HIV-infected patients. New England Journal of Medicine (2007). — www.nejm.org/doi/full/10.1056/NEJMoa072375
- Stanley TL et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA (2014). — jamanetwork.com/journals/jama/fullarticle/1900213
- FDA — Egrifta (tesamorelin) prescribing information and approval history. — www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505lbl.pdf
- Stanley TL et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV. The Lancet HIV (2019). — www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(19)30338-8/fulltext
Considering Tesamorelin?
A Kindr Health physician reviews every longevity intake — peptides are prescribed only when medically indicated based on your history and labs. There is no charge for the initial review.
Start your longevity intake →Related peptides
Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026
Last reviewed May 10, 2026. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products. Prescriptions require a clinical evaluation; a Kindr Health physician determines eligibility. Not for use in pregnancy. This page provides educational information and is not medical advice.